Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Trump administration seeks cuts in production of abused opioids

The Trump administration said it was proposing that U.S. pharmaceutical companies cut production of the six most abused opioids by 10 percent next year.

Read More »

Biogen’s muscle drug Spinraza too costly for Britain

Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.

Read More »

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics set an average price of $315,000 per year for the company’s newly approved Fabry disease treatment.

Read More »

India’s Hetero pulls heart drug from U.S.

A unit of India’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States amid a wider probe into cancer risks associated with the drug.

Read More »

GW Pharmaceuticals Slaps Price Tag on Cannabis-Based Epilepsy Drug

GW Pharmaceuticals revealed a $32,500 price for the company’s cannabis-based epilepsy drug Epidiolex.

Read More »

Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate

There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.

Read More »

Trump says will make announcement on reducing drug prices

U.S. President Donald Trump said his administration would make an announcement on reducing drug prices, but he did not offer specifics.

Read More »

Bayer wins EU watchdog’s endorsement for wider Xarelto use

Bayer received the European Medicines Agency’s recommendation for widening the use of its blockbuster clot prevention drug Xarelto to include atherosclerosis patients, opening a potentially lucrative new market.

Read More »

Amgen’s new migraine drug hits insurance hurdles

Amgen Inc.’s push to get patients on its new $575 a month migraine drug before competition emerges in September 2018 is facing barriers from insurers.

Read More »

Bayer to phase out Essure birth control device in U.S.

Bayer will discontinue the sale of the healthcare company’s birth control product Essure in the United States.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom